Second Admission of Shares | 07-Jun-2024 | 07:00 | RNS |
Publication of Annual Report & Notice of AGM | 03-Jun-2024 | 17:45 | RNS |
Supply of Products to New US Customer | 23-May-2024 | 07:00 | RNS |
Exercise of Share Options and Total Voting Rights | 15-May-2024 | 14:45 | RNS |
Final Results | 14-May-2024 | 07:00 | RNS |
Fundraise, RCF Extension, Termination of CLN & TVR | 10-May-2024 | 07:00 | RNS |
Product Supplied to First Two Sales Contracts | 14-Dec-2023 | 07:00 | RNS |
Fundraise, Update on Future CLN Financing & TVR | 12-Dec-2023 | 14:00 | RNS |
New European Sales Contract | 16-Nov-2023 | 07:00 | RNS |
Fundraise, CLN Issue, Joint Broker Appointed & TVR | 13-Oct-2023 | 07:00 | RNS |
Interim Results | 28-Sep-2023 | 07:00 | RNS |
Notice of Results and Investor Presentation | 18-Sep-2023 | 07:00 | RNS |
New Sales Contract with UK Pharmaceutical Company | 05-Sep-2023 | 07:00 | RNS |
Approval to roll-out chronic pain clinical trial | 01-Aug-2023 | 07:00 | RNS |
Result of AGM | 29-Jun-2023 | 17:30 | RNS |
Currency | UK Pounds |
Share Price | 83.00p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 163.50p |
52 Week Low | 79.00p |
Volume | 32,353 |
Shares Issued | 65.74m |
Market Cap | £54.57m |
RiskGrade | 111 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
No dividends found |
Time | Volume / Share Price |
17:08 | 1,000 @ 83.00p |
16:35 | 503 @ 83.00p |
16:35 | 503 @ 83.00p |
14:59 | 8,599 @ 80.67p |
14:50 | 40 @ 85.00p |
CEO | James Short |
CFO | Jonathan Turner |
You are here: research